Identification of Key Blood Molecular Markers for Immunotherapy

NCT00507702 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 191

Last updated 2019-04-18

No results posted yet for this study

Summary

To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.

Conditions

Interventions

PROCEDURE

phlebotomy

Standard of care

Sponsors & Collaborators

Principal Investigators

  • Jeffrey A. Norton · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-06
Primary Completion
2015-02-25
Completion
2015-02-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00507702 on ClinicalTrials.gov